Cite

    Ronald F van Vollenhoven et al.. “Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.” Annals of the rheumatic diseases, vol. 72, no. 9, 2013, pp. 1496–1502. http://access.bl.uk/ark:/81055/vdc_100137785565.0x000058